Multiple serological biomarkers for colorectal cancer detection
Multiple serological biomarkers for colorectal cancer detection
复制标题
DOI：
10.1002/ijc.24912
复制
发表时间：
2010-04-01
影响因子：
6.4
通讯作者：
Chan, Err-Cheng
中科院分区：
文献类型：
--
作者：
Chan, Chung-Chuan;Fan, Chung-Wei;Chan, Err-Cheng
本研究的目的是启动一个调查的人类自身抗体反应的选择大肠癌相关抗原的面板确定了先前的血清学分析的cDNA表达文库，并随后确定多种血清学生物标志物检测大肠癌。采用酶联免疫吸附试验（ELISA）检测了94例大肠癌患者和54例正常人血清中抗大肠癌相关抗原的自身抗体，以rCCCAP、rHDAC 5、rP 53、rNMDAR和rNY-CO-16蛋白为包被抗原。结直肠癌患者对5种单独包被抗原的血清阳性率从18.1%到35.1%不等。对5种包被抗原中任何一种的血清阳性率为58.5%，将该分析与血清癌胚抗原（>= 5 ng/ml）的评价相结合，血清阳性率显著增加至77.6%。早期（Dukes'stage A和B）结直肠癌患者对CEA的血清阳性率为21.9%，对5种结直肠癌相关抗原中的任一种的血清阳性率为53.7%，这2种测量的组合导致比单独的任一标记物更高的诊断能力（65.9%）。总之，这些结果共同表明，针对我们的结直肠肿瘤相关抗原组的血清自身抗体谱的联合检测和癌胚抗原的分析为结直肠癌提供了有希望的诊断生物标志物，特别是在早期患者中。
The aim of this study was to initiate a survey of human autoantibody responses to a panel of select colorectal tumor-associated antigens identified by previous serological analysis of a cDNA expression library and to subsequently identify multiple serological biomarkers for the detection of colorectal cancer. For screening of autoantibodies against colorectal tumor-associated antigens, sera from 94 colorectal cancer patients and 54 normal controls were analyzed by enzyme-linked immunosorbent assay using recombinant rCCCAP, rHDAC5, rP53, rNMDAR and rNY-CO-16 proteins as coating antigens. Seropositivity among colorectal cancer patients to the 5 individual coating antigens varied from 18.1% to 35.1%. Seropositivity to any of the 5 coating antigens was 58.5% and combining this analysis with evaluation of serum carcinoembryonic antigen (>= 5 ng/ml) significantly increased the seropositivity to 77.6%. Seropositivity of early-stage (Dukes' Stages A and B) colorectal cancer patients to CEA was 21.9%, and seropositivity to any of the 5 colorectal cancer-associated antigens was 53.7%, and the combination of these 2 measurements resulted in a higher diagnostic capacity (65.9%) than either marker alone. In conclusion, these results collectively indicated that combined detection of serum autoantibody profiles against our panel of colorectal tumor-associated antigens and the analysis of carcinoembryonic antigen provides a promising diagnostic biomarker for colorectal cancer, particularly among early-stage patients.